These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 11181800)

  • 1. Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy.
    Hoffmann MM; Scharnagl H; Panagiotou E; Banghard WT; Wieland H; März W
    J Am Soc Nephrol; 2001 Mar; 12(3):524-530. PubMed ID: 11181800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein E2-Dunedin (228 Arg replaced by Cys): an apolipoprotein E2 variant with normal receptor-binding activity.
    Wardell MR; Rall SC; Brennan SO; Nye ER; George PM; Janus ED; Weisgraber KH
    J Lipid Res; 1990 Mar; 31(3):535-43. PubMed ID: 2341812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein E2 (Arg136 --> Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia.
    März W; Hoffmann MM; Scharnagl H; Fisher E; Chen M; Nauck M; Feussner G; Wieland H
    J Lipid Res; 1998 Mar; 39(3):658-69. PubMed ID: 9548597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia.
    Horie Y; Fazio S; Westerlund JR; Weisgraber KH; Rall SC
    J Biol Chem; 1992 Jan; 267(3):1962-8. PubMed ID: 1730728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia.
    Ji ZS; Fazio S; Mahley RW
    J Biol Chem; 1994 May; 269(18):13421-8. PubMed ID: 8175773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virus-mediated transduction of apolipoprotein E (ApoE)-sendai develops lipoprotein glomerulopathy in ApoE-deficient mice.
    Ishigaki Y; Oikawa S; Suzuki T; Usui S; Magoori K; Kim DH; Suzuki H; Sasaki J; Sasano H; Okazaki M; Toyota T; Saito T; Yamamoto TT
    J Biol Chem; 2000 Oct; 275(40):31269-73. PubMed ID: 10903326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperlipidemia of ApoE2(Arg(158)-Cys) and ApoE3-Leiden transgenic mice is modulated predominantly by LDL receptor expression.
    van Dijk KW; van Vlijmen BJ; de Winther MP; van 't Hof B; van der Zee A; van der Boom H; Havekes LM; Hofker MH
    Arterioscler Thromb Vasc Biol; 1999 Dec; 19(12):2945-51. PubMed ID: 10591674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoprotein E isoforms and rare mutations: parallel reduction in binding to cells and to heparin reflects severity of associated type III hyperlipoproteinemia.
    Mann WA; Meyer N; Weber W; Meyer S; Greten H; Beisiegel U
    J Lipid Res; 1995 Mar; 36(3):517-25. PubMed ID: 7775863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease.
    Marais AD
    Pathology; 2019 Feb; 51(2):165-176. PubMed ID: 30598326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic factors precipitating type III hyperlipoproteinemia in hypolipidemic transgenic mice expressing human apolipoprotein E2.
    Huang Y; Rall SC; Mahley RW
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2817-24. PubMed ID: 9409260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apolipoprotein E-related glomerular disorders.
    Saito T; Matsunaga A; Fukunaga M; Nagahama K; Hara S; Muso E
    Kidney Int; 2020 Feb; 97(2):279-288. PubMed ID: 31874799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human apolipoprotein E7:lysine mutations in the carboxy-terminal domain are directly responsible for preferential binding to very low density lipoproteins.
    Dong J; Balestra ME; Newhouse YM; Weisgraber KH
    J Lipid Res; 2000 Nov; 41(11):1783-9. PubMed ID: 11060347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of hypercholesterolemia in apolipoprotein E2 and apolipoprotein E3-Leiden transgenic mice by adenovirus-mediated gene transfer of the VLDL receptor.
    van Dijk KW; van Vlijmen BJ; van der Zee A; van't Hof B; van der Boom H; Kobayashi K; Chan L; Havekes LM; Hofker MH
    Arterioscler Thromb Vasc Biol; 1998 Jan; 18(1):7-12. PubMed ID: 9445249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype.
    Kypreos KE; Li X; van Dijk KW; Havekes LM; Zannis VI
    Biochemistry; 2003 Aug; 42(33):9841-53. PubMed ID: 12924933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia.
    Dong LM; Parkin S; Trakhanov SD; Rupp B; Simmons T; Arnold KS; Newhouse YM; Innerarity TL; Weisgraber KH
    Nat Struct Biol; 1996 Aug; 3(8):718-22. PubMed ID: 8756331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The carboxyl terminus in apolipoprotein E2 and the seven amino acid repeat in apolipoprotein E-Leiden: role in receptor-binding activity.
    Dong LM; Innerarity TL; Arnold KS; Newhouse YM; Weisgraber KH
    J Lipid Res; 1998 Jun; 39(6):1173-80. PubMed ID: 9643348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired secretion of apolipoprotein E2 from macrophages.
    Fan D; Qiu S; Overton CD; Yancey PG; Swift LL; Jerome WG; Linton MF; Fazio S
    J Biol Chem; 2007 May; 282(18):13746-53. PubMed ID: 17341585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrophage-derived apoESendai suppresses atherosclerosis while causing lipoprotein glomerulopathy in hyperlipidemic mice.
    Tavori H; Fan D; Giunzioni I; Zhu L; Linton MF; Fogo AB; Fazio S
    J Lipid Res; 2014 Oct; 55(10):2073-81. PubMed ID: 25183802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biophysical analysis of apolipoprotein E3 variants linked with development of type III hyperlipoproteinemia.
    Georgiadou D; Chroni A; Vezeridis A; Zannis VI; Stratikos E
    PLoS One; 2011; 6(11):e27037. PubMed ID: 22069485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of
    Bea AM; Larrea-Sebal A; Marco-Benedi V; Uribe KB; Galicia-Garcia U; Lamiquiz-Moneo I; Laclaustra M; Moreno-Franco B; Fernandez-Corredoira P; Olmos S; Civeira F; Martin C; Cenarro A
    Arterioscler Thromb Vasc Biol; 2023 Jun; 43(6):1066-1077. PubMed ID: 37051929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.